Anugerah 88 Logo
$20.30+0.23|(+1.15%)
52W H: 21.17552W L: 9.56Beta: 1.23

About Amneal Pharmaceuticals Inc

  • Industry: Pharmaceuticals
  • Exchange: NASDAQ NMS - GLOBAL MARKET
  • Country: US
  • Website: https://amneal.com/

Frequently Asked Questions

What is the 52-week range for AMRX?

The 52-week high is $21.175 and the 52-week low is $9.56.

What is the P/E ratio for AMRX?

The Price to Earnings (P/E) ratio is 41.20.

What is the dividend yield for AMRX?

This company does not currently pay a dividend or the data is unavailable.

What is the Return on Equity (ROE)?

The trailing twelve months (TTM) Return on Equity is 174.61%.

What is the Net Profit Margin?

The Net Profit Margin (TTM) is 5.05%.

What is the Price to Book (P/B) Ratio?

The annual Price to Book ratio stands at 140.74.

Analyst Recommendation Trends

Wall Street analyst consensus for AMRX over the last few months:

2026-09-01
Buy: 7
S.Buy: 3
Hold: 1
Sell: 0
2026-08-01
Buy: 7
S.Buy: 3
Hold: 1
Sell: 0
2026-07-01
Buy: 7
S.Buy: 2
Hold: 1
Sell: 0
2026-06-01
Buy: 8
S.Buy: 2
Hold: 1
Sell: 0

Latest AMRX News

Amneal Pharmaceuticals (AMRX) Stock Gets Fair Value Bump After Analyst Backing For New Launches

The analyst fair value estimate for Amneal Pharmaceuticals has shifted from US$22.00 to about US$22.71 per share, reflecting updated price targets within the US$20 to US$27 range that are guiding much of the current discussion. Analysts are tying these targets to how effectively Amneal Pharmaceuticals turns its new products, biosimilars platform, and recent acquisitions into durable earnings power. As you read on, you will see how this evolving narrative may shape your own view of the stock’s...

Yahoo10/3/2026

Oppenheimer Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $27

Oppenheimer analyst Les Sulewski initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $27.

Benzinga9/23/2026

Amneal: Even My Bull Case Barely Justifies $20/Share

Amneal gets a Hold rating as improved business prospects are offset by dilution and higher debt. Click to read more about the AMRX stock.

SeekingAlpha9/22/2026

Why Is Amneal (AMRX) Stock Rocketing Higher Today

Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 12.5% in the afternoon session after the company announced that the U.S. Food and Drug Administration approved its generic lanreotide injection for immediate launch.

Yahoo9/22/2026

Amneal Announces FDA Approval and Launch of Lanreotide Injection

- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production BRIDGEWATER, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its lanreotide injection, 120 mg/0.5 mL, in a sterile, single-dose prefilled syringe. The product references SOMATULINE® Depot and will launch imme

Yahoo9/18/2026

3 Reasons to Avoid AMRX and 1 Stock to Buy Instead

What a time it’s been for Amneal. In the past six months alone, the company’s stock price has increased by a massive 47.7%, reaching $18.31 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Yahoo9/18/2026

Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?

Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Yahoo9/17/2026

Salesforce To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday

Wall Street analysts made mixed price-target changes for LYFT, AMRX, JBHT, CRM, APPF, FLNC and CRWD.

Benzinga9/17/2026

Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $20

Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $16 to $20.

Benzinga9/17/2026

Insider Unloading: KEVIN BUCHI Sells Options, Realizes $54K

A large exercise of company stock options by KEVIN BUCHI, Board Member at Amneal Pharmaceuticals (NASDAQ:AMRX) was disclosed in a new SEC filing on September 14, as part of an insider exercise. What Happened: Disclosed

Benzinga9/15/2026

Leerink Partners Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $23

Leerink Partners analyst Daniel Clark initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $23.

Benzinga9/9/2026

Does Amneal’s Post‑Earnings Shelf Registration Reshape the Bull Case for Amneal Pharmaceuticals (AMRX)?

In early September 2026, Amneal Pharmaceuticals filed a shelf registration for up to US$522.69 million of Class A common shares, covering 28,942,098 securities, shortly after reporting a very strong second-quarter performance with revenue of US$796.2 million and an increase of 9.9% year on year. The combination of an impressive earnings beat, raised full-year EPS guidance, and a large new shelf registration raised questions about how Amneal might balance growth investments with the potential...

Yahoo9/5/2026

Amneal Pharmaceuticals (AMRX) Bets Big On Biosimilars While Wall Street Retreats

On August 10, Amneal Pharmaceuticals (NASDAQ:AMRX) completed its acquisition of Kashiv BioSciences, a deal that co-CEO Chirag Patel called a pivotal step in the company’s push to become America’s top Affordable Medicines company. The combination pairs Kashiv’s biologics research and manufacturing with Amneal’s commercial reach, giving Amneal a rare end-to-end presence in biosimilars. It is […]

Yahoo9/4/2026

Amneal Pharmaceuticals (AMRX) Stock Sees Modest Fair Value Lift On Launch Optimism

Amneal Pharmaceuticals is back in focus after analysts lifted fair value from US$20.25 to US$21.00 per share, reflecting updated assumptions in recent models. Much of this shift lines up with Street research that leans positive on growth, execution, and the potential from new product launches and a broader portfolio. Keep reading to see what is changing in the narrative around Amneal Pharmaceuticals and how you can track those moving parts over time. Stay updated as the Fair Value for Amneal...

Yahoo9/4/2026

Amneal Pharmaceuticals Files Prospectus Related To The Offer And Sale Of Up To 28,942,098 Shares of Class A Common Stock By Selling Stockholders

https://www.sec.gov/Archives/edgar/data/1723128/000114036126035617/ny20081412x1_s3asr.htm

Benzinga9/3/2026

Generic Pharmaceuticals Stocks Q2 Results: Benchmarking Amneal (NASDAQ:AMRX)

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers.

Yahoo9/3/2026

Related Stocks (Peers)

Companies operating in similar sectors to AMRX:

TARSMBXLQDASUPNAMRXHRMYVRNO.NEPBHGPCRTRLVLLY

Recent Insider Transactions

DateNameShares ChangedPriceValue
2026-09-17BUCHI J KEVIN-20,445--
2026-09-11BUCHI J KEVIN-20,445--
2026-09-11BUCHI J KEVIN+20,445$14.45$295,430
2026-09-01BOYER ANDREW S-80,000--
2026-08-21BOYER ANDREW S-152,426--
2026-08-13Kiely John-10,000--
2026-08-13Kiely John-50,000$17.64$882,000
2026-08-12Shah Nikita-146,403$17.51$2,563,517
2026-08-12Daly Jason B.-210,000$17.4$3,654,000
2026-08-11Daly Jason B.-6,613$17.7$117,050
2026-08-11BUCHI J KEVIN-168,573$17.18$2,896,084
2026-08-10Patel Chintu+6,381,734--
2026-08-10Patel Gautam+283,632--
2026-08-10Patel Chirag K.+6,381,734--
2026-08-10Patel Tushar Bhikhubhai+12,763,469--
2026-05-11Autor Deborah M.-34,819$12.94$450,558
2026-05-07Kiely John-34,819--
2026-05-07Kiely John+34,819--
2026-05-07Autor Deborah M.-34,819--
2026-05-07Autor Deborah M.+34,819--
2026-05-07George Jeffrey P.-34,819--
2026-05-07George Jeffrey P.+34,819--
2026-05-07Patel Gautam-34,819--
2026-05-07Patel Gautam+34,819--
2026-05-07Yanai Shlomo-34,819--
2026-05-07Yanai Shlomo+34,819--
2026-05-07Nark Ted C-34,819--
2026-05-07Nark Ted C+34,819--
2026-05-07BUCHI J KEVIN-34,819--
2026-05-07BUCHI J KEVIN+34,819--
2026-05-07MEISTER PAUL M-48,747--
2026-05-07MEISTER PAUL M+48,747--
2026-05-06Kiely John+19,824--
2026-05-06Autor Deborah M.+19,824--
2026-05-06George Jeffrey P.+19,824--
2026-05-06Patel Gautam+19,824--
2026-05-06Yanai Shlomo+19,824--
2026-05-06Nark Ted C+19,824--
2026-05-06BUCHI J KEVIN+19,824--
2026-05-06MEISTER PAUL M+30,837--
2026-03-04Patel Chintu-92,593--
2026-03-04Patel Chintu-28,983$13.3$385,474
2026-03-04Patel Chintu+92,593--
2026-03-04Patel Chirag K.-92,593--
2026-03-04Patel Chirag K.-37,825$13.3$503,073
2026-03-04Patel Chirag K.+92,593--
2026-03-04Daly Jason B.-35,880--
2026-03-04Daly Jason B.-15,580$13.3$207,214
2026-03-04Daly Jason B.+35,880--
2026-03-04Shah Nikita-35,880--
2026-03-04Shah Nikita-17,976$13.3$239,081
2026-03-04Shah Nikita+35,880--
2026-03-04Konidaris Tasos-49,982--
2026-03-04Konidaris Tasos-22,035$13.3$293,066
2026-03-04Konidaris Tasos+43,982--
2026-03-04BOYER ANDREW S-38,195--
2026-03-04BOYER ANDREW S-19,136$13.3$254,509
2026-03-04BOYER ANDREW S+38,195--
2026-03-03Patel Chintu-733,944--
2026-03-03Patel Chintu-59,931--
2026-03-03Patel Chintu-315,885$13.31$4,204,429
2026-03-03Patel Chintu+733,944--
2026-03-03Patel Chintu-17,112$13.31$227,761
2026-03-03Patel Chintu+59,931--
2026-03-03Patel Chirag K.-733,944--
2026-03-03Patel Chirag K.-59,931--
2026-03-03Patel Chirag K.-297,537$13.31$3,960,217
2026-03-03Patel Chirag K.+733,944--
2026-03-03Patel Chirag K.-15,616$13.31$207,849
2026-03-03Patel Chirag K.+59,931--
2026-03-03Daly Jason B.-305,810--
2026-03-03Daly Jason B.-24,258--
2026-03-03Daly Jason B.-38,226--
2026-03-03Daly Jason B.-22,645--
2026-03-03Daly Jason B.-132,783$13.31$1,767,342
2026-03-03Daly Jason B.+305,810--
2026-03-03Daly Jason B.-10,533$13.31$140,194
2026-03-03Daly Jason B.+24,258--
2026-03-03Daly Jason B.-16,598$13.31$220,919
2026-03-03Daly Jason B.+38,226--
2026-03-03Daly Jason B.-10,147$13.31$135,057
2026-03-03Daly Jason B.+22,645--
2026-03-03Shah Nikita-366,972--
2026-03-03Shah Nikita-23,544--
2026-03-03Shah Nikita-45,871--
2026-03-03Shah Nikita-36,232--
2026-03-03Shah Nikita-183,853$13.31$2,447,083
2026-03-03Shah Nikita+366,972--
2026-03-03Shah Nikita-11,796$13.31$157,005
2026-03-03Shah Nikita+23,544--
2026-03-03Shah Nikita-22,982$13.31$305,890
2026-03-03Shah Nikita+45,871--
2026-03-03Shah Nikita-18,502$13.31$246,262
2026-03-03Shah Nikita+36,232--
2026-03-03Konidaris Tasos-458,716--
2026-03-03Konidaris Tasos-28,538--
2026-03-03Konidaris Tasos-57,339--
2026-03-03Konidaris Tasos-45,290--
2026-03-03Konidaris Tasos-229,817$13.31$3,058,864
2026-03-03Konidaris Tasos+458,716--
2026-03-03Konidaris Tasos-14,298$13.31$190,306
2026-03-03Konidaris Tasos+28,538--
2026-03-03Konidaris Tasos-24,251$13.31$322,781
2026-03-03Konidaris Tasos+57,339--
2026-03-03Konidaris Tasos-16,182$13.31$215,382
2026-03-03Konidaris Tasos+45,290--
2026-03-03BOYER ANDREW S-397,554--
2026-03-03BOYER ANDREW S-24,258--
2026-03-03BOYER ANDREW S-49,694--
2026-03-03BOYER ANDREW S-39,252--
2026-03-03BOYER ANDREW S-199,175$13.31$2,651,019
2026-03-03BOYER ANDREW S+397,554--
2026-03-03BOYER ANDREW S-12,154$13.31$161,770
2026-03-03BOYER ANDREW S+24,258--
2026-03-03BOYER ANDREW S-24,897$13.31$331,379
2026-03-03BOYER ANDREW S+49,694--
2026-03-03BOYER ANDREW S-19,945$13.31$265,468
2026-03-03BOYER ANDREW S+39,252--
2026-03-02Patel Chintu+544,663--
2026-03-02Patel Chirag K.+544,663--
2026-03-02Shah Nikita+65,359--
2026-03-02Shah Nikita+65,359--
2026-03-02Patel Chintu+354,031--
2026-03-02Patel Chintu+190,632--
2026-03-02Patel Chirag K.+354,031--
2026-03-02Patel Chirag K.+190,632--
2026-03-02Daly Jason B.+65,359--
2026-03-02Daly Jason B.+65,359--
2026-03-02Konidaris Tasos+72,622--
2026-03-02Konidaris Tasos+72,622--
2026-03-02BOYER ANDREW S+65,359--
2026-03-02BOYER ANDREW S+65,359--
2025-11-17Nark Ted C-50,000$11.72$586,000
2025-11-12Shah Nikita-95,525--
2025-11-12Shah Nikita-36,331--
2025-11-12Shah Nikita-131,856$11.92$1,571,724
2025-11-12Shah Nikita+95,525$2.75$262,694
2025-11-12Shah Nikita+36,331$2.75$99,910